Deutsche Bank analyst George Hill lowered the firm’s price target on UnitedHealth (UNH) to $328 from $362 and keeps a Buy rating on the shares ahead of the Q2 report. The firm says investor sentiment on the shares “has deteriorated significantly” due to a series of negative headlines and industry headwinds. Deutsche reduced estimates ahead of the earnings report, saying Optum Health remains its biggest concern.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNH:
- UnitedHealth Stock Collapse Continues: Here’s What This Investor Thinks Will Happen Next
- Who Is TipRanks’ All-Star Analyst on UnitedHealth Stock (UNH)?
- ACA marketplace plans seek double digit rate increases for 2026, WSJ says
- U.S. Health insurers prescription drug denials on the rise, NYT says
- Bernstein Calls UnitedHealth Stock (UNH) a Top Pick Ahead of Q2 Earnings